TP53 and pancreatic neoplasm: The Kawamura et al. study also described their in-house MTH1-specific inhibitors (NPD7155 and NPD9948), and reported minimal effects on viability and DNA damage markers in several pancreatic cancer cell lines (the p53- and KRAS-mutant MiaPaCa-2 and PANC-1 lines), as well as HeLa and Jurkat cells, which have a tendency to accumulate p53 mutations or deletions in culture.